Antibody-drug Conjugates or ADCs are highly targeted biopharmaceutical drugs that combine monoclonal antibodies specific to surface antigens present on particular tumor cells with highly potent anti-cancer agents linked via a chemical linker. The linker plays a key role in determining the pharmacokinetic properties, therapeutic index, selectivity and the overall success of the ADC.
PEG-linkers are particularly attractive as a linker for conjugation. Water solubility, lack of toxicity; low immunogenicity and well defined chain lengths and molecular weights are specific characteristics of PEG moieties relevant to pharmaceutical applications.
Biochempeg develops a broad range of PEG linkers and provides custom linker synthesis for clients worldwide.